New Treatment of Common Wart

this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.

Inclusion Criteria: * \- Age more than or equal to 18 years * Clinically and dermoscopically confirmed Common warts of both sex * patient not receiving previous treatment at least one month before recruitment in our study * Single or multiple lesions suitable for injection. Exclusion Criteria: * Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions . Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .